Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2021-04-29 2021-04-29
Drug Identification Number 02403188 02403188
Brand name CISPLATIN INJECTION CISPLATIN INJECTION
Common or Proper name CISPLATIN INJECTION 1MG/ML CISPLATIN INJECTION 1MG/ML
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients CISPLATIN CISPLATIN
Strength(s) 1.0MG 1.0MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 50ml 50ml
ATC code L01XA L01XA
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-02-03 2021-02-03
Estimated end date 2021-04-30 2021-04-30
Actual end date 2021-04-28 2021-04-28
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments
Health Canada comments